Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Abstract Background Inhaled glucocorticoid corticosteroid (ICS), long-acting β2-adrenoceptor agonist (LABA), and other drugs have limited therapeutic effects on COPD with significant individual differences. Traditional Chinese medicine (TCM)-modified Bushen Yiqi formula (MBYF) demonstrates advantage...

Full description

Bibliographic Details
Main Authors: Qing Kong, Yuxue Cao, Zhen Gao, Jing Sun, Hongying Zhang, Yijie Du, Yubao Lv, Sihan Zhou, Zihui Tang, Baojun Liu, Jingcheng Dong
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Trials
Subjects:
Online Access:https://doi.org/10.1186/s13063-022-06057-7